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Tissue Inhibitor ofmetalloproteinases-3 (TIMP-3) is a potent
matrix-bound angiogenesis inhibitor. Mutations in TIMP-3
cause Sorsby Fundus Dystrophy, a dominant inherited, early
onset macular degenerative disease, with choroidal neovascu-
larization causing a loss of vision in the majority of patients.
Here we report that expression of S156C TIMP-3 mutation in
endothelial cells results in an abnormal localization of the pro-
tein, increased glycosylation, decreased matrix metalloprotein-
ase inhibitory activity, and increased vascular endothelial
growth factor (VEGF) binding with a consequent increase in
VEGF-dependent migration and tube formation. These
enhanced signaling events appear to be mediated as a conse-
quence of a post-transcriptionally regulated increase in the
expression of membrane-associated VEGFR-2 in endothelial
cells of Timp-3156/156 mutant mice as well as in human Sorsby
fundus dystrophy eyes. Understanding the mechanism(s) by
whichmutant TIMP-3 can induce abnormal neovascularization
provides important insight into the pathophysiology of a num-
ber of diseases with increased angiogenesis.
Tissue inhibitor of metalloproteinases-3 (TIMP-3)2 is a
member of the TIMP family of proteins and is an endogenous
inhibitor of matrix metalloproteinases (MMPs), a disintegrin
and metalloproteinase (ADAM), and ADAM with throm-
bospondin domains (ADAMTS) family of enzymes. TIMP-3 is
unique among other members of the TIMP family in that it is
tightly bound to the extracellular matrix (ECM). In addition,
TIMP-3 is the only TIMP that can inhibit tumor necrosis factor
-converting enzyme (TACE/ADAM17) and aggrecanase 1
and 2 (ADAMTS4 and ADAMTS5). Functionally, apart from
being a key inhibitor ofMMPs (1, 2) and regulating apoptosis in
some cells in vitro and in vivo (3–7), TIMP-3 has been demon-
strated to be a potent inhibitor of angiogenesis through its abil-
ity to block the binding of VEGF to its receptor VEGFR-2 (also
known as KDR and FLK-1), affecting subsequent receptor
downstream signaling (8). TIMP-3 protein is produced consti-
tutively by the retina pigment epithelium (RPE) and choroidal
endothelial cells (9, 10) in the eye and is a component of the
normal Bruch membrane (11). Sorsby fundus dystrophy (SFD)
(12), a dominantly inherited, degenerative disease of the mac-
ula, is caused by specificmutations in theTIMP-3 gene (13–20),
most of which introduce an unpaired cysteine at theC terminus
of the protein. SFD is of considerable interest as it is the only
genetic disorder in which choroidal neovascularization occurs
in the majority of affected patients (21–23). SFD-TIMP-3 pro-
tein accumulates in deposits in Bruch membrane (24) and
shows pro-apoptotic activity (25) and reducedMMP inhibitory
activity (10). Whether SFD-TIMP-3 affects VEGFR-2-medi-
ated VEGF signaling specific to angiogenesis is unknown. In
this study we have generated endothelial cells (ECs) expressing
SFD-related S156C TIMP-3 mutation as a platform and deter-
mined how mutant TIMP-3 regulates VEGF signaling via
VEGFR-2 during SFD-related angiogenesis. In addition, we
have analyzed retinas from mice carrying the related S156C
mutation and a postmortem human eye with SFD to confirm
our experimental results.
EXPERIMENTAL PROCEDURES
Materials—Porcine aortic endothelial (PAE and PAEKDR)
cells were cultured in Ham’s F-12/Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT), 50 unit/ml penicillin, and 50 g/ml streptomycin
as described previously (10). Recombinant human VEGF was a
kind gift from Genentech. Antibodies were monoclonal anti-
TIMP-3 antibody (Chemicon International, Inc., Temecula,
CA), monoclonal anti-Flk-1 (A-3), goat polyclonal anti-actin
(C-11), and bovine anti-goat lgG-horseradish peroxidase (Santa
Cruz Biotechnology, Santa Cruz, CA)), polyclonal phospho-
VEGF receptor-2/3 (Ab-1) antibody (OncogeneTM Research
Products, Cambridge, MA), monoclonal anti-VEGF receptor-2
(KDR), clone KDR-2, (Sigma), mitogen-activated protein
kinase (MAPK), and phospho-specific MAPK antibodies (Cal-
biochem-Novabiochem), and horseradish peroxidase-conju-
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gated anti-rabbit and anti-mouse IgG antibodies (GE Health-
care). Post-mortem control non-diseased age-matched eyes
were obtained from National Disease Research Interchange,
National Resource Center, Philadelphia.
Generation of EC Cell Lines Expressing Wild-type or S156C
Mutant TIMP-3—A 550-bp Timp-3 or S156C Timp-3 insert
from a human cDNA clone was cloned into expression vector
pCEP4 (Invitrogen). PAEKDR cells were transfected with
Timp-3 cDNA (WT or mutant) or empty vector using Lipo-
fectamine reagent (Invitrogen). Stable clones were isolated
using hygromycin selection. RT-PCR, Western blot, and
reverse zymography were used to identify and analyze the
expression of TIMP-3 or mutant TIMP-3, respectively.
RT-PCR—Total RNA was extracted from the cells by using
Totally RNATM kit (Ambion Inc., Austin, Texas). RT-PCR was
performed using a RETROscriptTM First Strand Synthesis kit
(Ambion). 10 ng of total RNA was used for RT and amplifica-
tion. The sequences of the PCR primer pairs for human
VEGFR-2 and TIMP-3 gene were 5-CTT CGA AGC ATC
AGC ATA AGA AAC T-3 (forward) and 5-TGG TCA TCA
GCC CAC TGG AT-3 (reverse) and 5-CTC TGC AAC TCC
GACATCGTGAT-3 (forward) and 5-CAGCAGGTACTG
GTA CTT GTT GAC-3 (reverse), respectively. 28 S primers
(forward, 5-GTTCACCCACTAATAGGGAACGTGA-3,
and reverse, 5-GATTCTGACTTAGAGGCGTTCAGT-3)
were used as a control for RNA expression. PCR conditions
were 94 °C for 3 min followed by 30 cycles (94 °C, 30 s; 55 °C,
30 s; 72 °C, 1 min) and a final extension step of 72 °C for 5.
Real-time PCR was performed to compare the levels of
VEGFR-2 in endothelial cells expressing WT or mutant
TIMP-3. Complementary DNA was synthesized by reverse
transcription of total RNA (1 g) using the iScript cDNA syn-
thesis kit (Bio-Rad). Real time PCR was performed on a DNA
Engine OpticonTM system (MJ Research/GMI, Ramsey, MN)
using brilliant SYBR green kit with a thermal profile of 94 °C for
2 min followed by 40 cycles of 94 °C for 30 s, 55 °C for 30 s, and
72 °C for 1 min. Results are expressed as CT values, where CT is
defined as the cycle number at which an increase above back-
ground fluorescence could be reliably detected, and CT is the
difference between theCT values of KDR and 28 S. Vector PAE/
KDR cDNA was used as calibrator to generate a CT value
(CT WT or mutant PAE/KDR sample-CT vector sample).
The -fold differential expression in KDR compared with cali-
brator was expressed as 2CT.
Preparation of Cellular Fractions—2-Day serum-free-condi-
tioned medium (CM) was collected from subconfluent cells
cultured on six-well plates. In some cases the CM was further
concentrated with heparin-agarose gels (Bio-Rad). The cell
monolayer was dislodged from the culture plates after a 10-min
incubation in Ca2-, Mg2-free phosphate-buffered saline
(PBS) containing 2.5mM EDTA. After several rinses in PBS and
water, the ECMwas scraped in a small volume of electrophore-
sis sample buffer without reducing agent for analyses.
Ligand Binding Assay—1  106 cells/well in 12-well plates
were incubated with the indicated concentrations of 125I-
VEGF165 (specific activity, 1805 Ci/mmol, GE Healthcare) in
the presence or absence of a 50-fold excess of unlabeled VEGF
for 2 h on ice. After washing, the cell monolayers were solubi-
lized with lysis buffer (20 mM Tris HCl, pH 7.5, 1% Triton
X-100, and 10%glycerol), and the radioactivitywasmeasured in
a gamma counter.
Immunoprecipitation and Immunoblotting—Cell fractions
or immunoprecipitates of the lysates with the indicated anti-
bodies were subjected to SDS-PAGE. Proteins were probed
with antibody and detected with either a horseradish peroxi-
dase-conjugated anti-rabbit or anti-mouse IgG antibody
(Amersham) followed by ECL. The blots were re-stripped with
Western ReProbeTM solution (GBiosciences, Maryland Heights,
MO) for 30min and reprobed as indicated.
Reverse Zymography—Conditionedmedium, cell lysates, and
ECM fractions from transfected cells were prepared as
described previously (10). Equal amounts of protein were
loaded onto a 12% gel with 1 mg/ml gelatin plus RPE cell-con-
ditioned media, as a source of MMPs, for reverse zymography
and processed as described previously (2).
Immunofluorescence Staining—For immunostaining, sub-
confluent cells cultured on Falcon culture slides (BD, Bio-
sciences) were used. For actin reorganization, cells were stim-
ulated for 15 min at 37 °C with 50 ng/ml VEGF or control
buffer. The cells were fixed with 3.7% paraformaldehyde in
PBS for 30 min at 4 °C and permeabilized with 0.2 Triton
X-100 for 20 min at room temperature. After rinsing with
PBS the cells were incubated with fluorescein isothiocya-
nate-labeled phalloidin in PBS (0.66 g/ml, Sigma) for 20
min at room temperature, washed with PBS, and analyzed by
fluorescence microscopy.
Proliferation Assay—Cells were seeded at a density of 5000
cells/well in 24-well culture plates and cultured for 24 h in
growth medium. After synchronization overnight in serum-
free medium supplemented with 0.1% BSA (Sigma), cells were
stimulated with or without VEGF for 36 h followed by the addi-
tion of 0.4 Ci/ml [3H]thymidine for 4 h. High molecular
weight DNA was precipitated using 5% trichloroacetic acid at
4 °C for 30 min. After two washes with ice-cold H20, 3H radio-
activity was solubilized in 1 N NaOH for 20 min at room tem-
perature, acidified by the addition of 2 N HCl, and measured
using a liquid scintillation counter. Each sample was assayed in
triplicate, and the assays were repeated at least twice.
Migration Assay—A modified Boyden chamber assay was
carried out as described previously (8). Briefly, 8.0-m pore
polyvinylpyrrolidone free polycarbonate membranes were pre-
coatedwith 100g/ml collagen type I in 0.2 N acetic acid (Cohe-
sion Technologies, Palo Alto, CA). VEGF at the indicated con-
centrationswas placed in the lower chamber, and cells (2 106)
in serum-freemediumwere placed in the upper chambers. The
chamber was then incubated for 4 h at 37 °C in a 5% CO2-
humidified incubator. Cells remaining on the top of the filter
were removed. Cells on the bottom surface of the filter were
fixed, stained, andmounted. The number of migrating cells per
well was counted microscopically.
Tube Formation Assay—Type 1 collagen was mixed with
10Dulbecco’smodified Eagle’smediumand 0.1MNaOH (8:1:
1), adjusted to a solution containing 10 g/ml growth factor-
reducedMatrigelmatrix (BDBiosciences), and then distributed
in 48-well dishes. After gelling, serum-starved cells were seeded
on the collagen gels at 1.5  104 cells/well and maintained in
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serum-free medium in the presence or absence of 50 ng/ml
VEGF. After 4 h of incubation at 37 °C, a second layer of colla-
gen was added, and cultures were kept under the same condi-
tions as described above. Tube formationwas examined using a
phase-contrast microscopy at the indicated time points.
Immunohistochemistry—For staining frozen sections, slides
were fixed in cold acetone for 10min and blockedwith 10%goat
serum in PBS containing 0.2% Triton X-100 for 1 h. Anti-
VEGFR-2 (1: 200) was then applied. After an overnight incuba-
tion at 4 °C, the antibody bindingwas resolvedwith Alexa Fluor
488-conjugated goat anti-mouse lgG (Invitrogen Molecular
Probes) or Texas Red-conjugated AffiniPure goat anti-mouse
lgG (Jackson ImmunoResearch Laboratories). Specificity of the
immunostaining was verified by substituting the primary anti-
bodywith an equivalent dilution of a nonspecific controlmouse
lgG. Slides were mounted in antifade medium containing 4,6-
diamidino-2-phenylindole for labeling nuclei (Vectashield;
Vector Laboratories, Inc., Burlingame, CA). Images were taken
with a confocal laser-scanning microscope or a fluorescence
microscope. For staining of paraffin sections, slides were depar-
affinized in xylene and rehydrated through an alcohol series.
Endogenous peroxidase was blocked by immersion in 0.3%
hydrogen peroxidase for 30 min. No antigen retrieval was
required except for factor VIII staining. Antibodies against
TIMP-3, VEGFR-2, and factor VIII (dilution 1: 200) were
applied overnight at 4 °C. The sections were processed further
using a Vectastain ABC kit and VectorR VIP substrate kit for
peroxidase (Vector Laboratories). Control sections were pro-
cessed in the same way with negative control rabbit and mouse
lgG.
Statistical Analysis—The p values were calculated from Stu-
dent’s t test or analysis of variance using comparisons with con-
trol samples tested at the same time.
RESULTS
S156C TIMP-3 Is Abnormally Distributed in Endothelial
Cells—Stable endothelial cell lines (PAEKDR) expressing wild-
type (WT) or S156C mutant TIMP-3 cDNA or vector alone
were generated. Two independent clones expressing similar
levels of mRNA (identified by RT-PCR) encoding WT (W1,
W4) or mutant TIMP-3 (M7, M10) were identified (Fig. 1A).
Western blot analysis using monoclonal antibodies against
TIMP-3 determined that in endothelial cells WT TIMP-3 was
predominantly localized in the ECM in a 23-kDa form (Fig. 1B,
upper panel) with a very small fraction secreted into the CM
(Fig. 1B, lower panel), confirming previous reports that TIMP-3
is an ECM-bound protein in endothelial cells (8). On the other
hand, mutant Ser-156 TIMP 3 was detected predominantly in
the CM as a 28-kDa protein (Fig. 1B), suggesting a possible
reduced ECM binding property for the mutant protein. To
determine whether the higher molecular weight form of
mutant TIMP-3 was a result of glycosylation, samples were
treated with peptideN-glycosidase F (an amidase that removes
N-linked glycoproteins) before analyses. This treatment
resulted in a conversion of the 28-kDa form to the 23-kDa form
(Fig. 1C), which suggests that the 28-kDa protein is a glyco-
sylated variant of mutant TIMP-3. The spatial expression of
mutant TIMP-3 and its molecular mass species in endothelial
cells are distinct from those observed in RPE cells (10, 26),
where themutant protein is expressed in the ECM like its wild-
type counterpart. The reason for this discrepancy is likely
because of unique distributions and expressions in different cell
types. TheMMP inhibitory activity ofWT andmutant TIMP-3
was further analyzed by reverse zymography. ECM and CM of
PAEKDR cells expressing WT TIMP-3 (W1, W4) showed a
marked MMP inhibitory species with an approximate molecu-
lar mass of 23 kDa corresponding to the protein visualized on
Western blot (Fig. 1D). However, the cells expressing mutant
TIMP-3 (M7,M10) exhibitedminimalMMP inhibitory activity
in CMor ECM samples (Fig. 1D), similar to our previous obser-
vations in RPE cells (10). A similar result was obtained byWest-
ern blot analyses (Fig. 1E) and reverse zymography (Fig. 1F) of
heparin-agarose-concentrated CM. These results indicate that
mutant Ser-156-TIMP-3 exhibits characteristics of an abnor-
FIGURE 1. Abnormal localization of S156C TIMP-3 in endothelial cells.
Analysis of WT TIMP-3 (W1 andW4), S156C TIMP-3 (M7 andM10) and control
vector-transfected (V) PAEKDR cells. A, total RNA extracts were analyzed for
TIMP-3 and 28S mRNAs by RT-PCR. B, the expression levels and cellular local-
izationofWTandS156CTIMP-3proteins in the ECMandCMweredetermined
by immunoblotting (Ib) with anti-TIMP-3 monoclonal antibodies. C, the ECM
and CMprepared frommutant cells were treatedwith peptideN-glycosidase
F (PGNase), and deglycosylation was analyzed by immunoblotting with anti-
TIMP-3 monoclonal antibody. WT TIMP-3 in the ECM was used as a positive
control for the unglycosylated form. D, TIMP (MMP inhibitory) activity in the
ECM (upper panel) andCM(lower panel)was analyzedby reverse zymography.
E, heparin-agarose-conditionedmedium fromWT andmutant cells was ana-
lyzed for TIMP-3 by immunoblotting with TIMP-3 monoclonal antibody.
F, heparin-agarose-conditioned medium fromWT andmutant cells was ana-
lyzed for TIMP-3 activity by reverse zymography.
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mal protein, including reduced binding to the ECMof endothe-
lial cells in addition to a reduction in MMP inhibitory activity.
S156C TIMP-3 Expression in ECs Increases VEGF Binding to
VEGFR-2—To determine whether expression of mutant
TIMP-3 regulates the interaction of VEGF with VEGFR-2, we
examined VEGF binding in parental PAE and the transfected
PAEKDR cell lines using a 125I-VEGF binding assay. Mock cells
(Fig. 2, V, PAEKDR cells transfected with empty vector) but not
parental PAE (P, ECs not expressing KDR) cells showed a spe-
cific concentration-dependent 125I-VEGF binding (data not
shown). As we have shown previously, WT TIMP-3 expression
dramatically inhibited the binding of 125I-VEGF to VEGFR-2,
with a downward shift of the concentration binding curve (Fig.
2, A and B). Surprisingly, the expression of mutant TIMP-3
resulted in a 2–3-fold increase in 125I-VEGF binding with an
upward shift in the concentration binding curve (Fig. 2, A
and B).
S156C TIMP-3 Expression in ECs Accentuates VEGFR-2 Sig-
naling via Elevated Receptor Levels—Because mutant cells
showed an increased VEGF binding to VEGFR-2, we tested
whether these cells had elevated levels of functional VEGFR-2
on their surface. Co-immunoprecipitation of VEGFR-2 fol-
lowed by Western blot analysis using an anti-phosphotyrosine
antibody demonstrated that VEGF stimulated the tyrosine
phosphorylation of a 210-kDa VEGFR-2 protein in cell lysates
prepared from both control transfected cells (V) and mutant
cells (M) (Fig. 2C). In contrast, as reported previously, no recep-
tor autophosphorylation was seen in WT TIMP-3 cells (Fig.
2C). Immunoprecipitation and Western blot analysis of cell
lysates with antibody directed against the C terminus of
VEGFR-2 in mock-transfected cells (V) showed a mature form
of VEGFR-2 corresponding to a molecular size of 210-kDa that
phosphorylated in response to VEGF. In addition, two other
receptor forms (a 200-kDa intermediate form and smaller frag-
ment (immature form) at 160 kDa) were also observed that
were not phosphorylated (Fig. 2D), consistent with previous
reports (27). There was a marked increase in intensity of the
mature form and intermediate form of the receptor in mutant
cells compared with WT TIMP-3 and control cells (Fig. 2D).
Activation of mitogen-activated protein kinase is a known
VEGFR-2 downstream signaling event.Wemeasured the phos-
phorylation of two mitogen-activated protein kinases, ERK1
(p44) and ERK2 (p42), byWestern blot analysis of cell lysates in
WT and mutant endothelial cells. VEGF stimulated the phos-
phorylation of ERK1/2 in mock cells (V) and mutant cells (M)
but not inWTTIMP-3 cells (Fig. 2E, upper panel), whereas the
expression of WT and mutant TIMP-3 had no impact on total
ERK1/2 levels (Fig. 2E, lower panel). These results determine
that elevated VEGFR-2 in mutant cells is associated with
enhanced activation of ERK1/2 when compared with cells
expressing WT TIMP-3. RT-PCR (Fig. 2F, lower panel) and
quantitative PCR analyses (Fig. 2F, upper panel) determined
thatmutant TIMP-3 does not up-regulate VEGFR-2/KDR gene
expression in endothelial cells. Overall, these data indicate that
mutant TIMP-3 potentiates VEGF-stimulated tyrosine phos-
phorylation of VEGFR-2 via elevated receptor levels on the cell
surface.
S156C TIMP-3 Enhances VEGF-stimulated Migration and
Actin Reorganization but Not Proliferation—To investigate
whether elevated VEGFR-2 signaling in cells expressing
mutant TIMP-3 could be translated into enhanced biological
responses, we examined VEGF-stimulated proliferation and
migration, two critical steps in the angiogenic process, in the
transfected PAEKDR cell lines. Quiescent endothelial cells
were stimulated with VEGF and evaluated by incorporation
of [3H]thymidine. As shown in Fig. 3A, left panel, VEGF
stimulated the proliferation of mock-transfected cells in a
concentration-dependent fashion with a maximum activity
at 15 ng/ml. Mutant cells exhibited similar mitogenic
responses to VEGF, whereas WT TIMP-3 cells showed a
dramatic attenuation in the VEGF response (Fig. 3A, right
panel), indicating that cells expressing mutant TIMP-3 is an
inefficient inhibitor of VEGF-stimulated EC proliferation.
A mini-Boyden chamber assay was used to examine VEGF-
stimulated cell migration. VEGF stimulated a concentration-
dependent migratory response in mock cells with a maximum
effect at 50 ng/ml (Fig. 3B, left panel). WT TIMP-3 expression,
but not mutant TIMP-3m dramatically reduced basal and
VEGF-stimulated migration. Mutant TIMP-3-expressing cells
had an accentuated migratory response toward VEGF (Fig. 3B,
right panel). EC migration involves reorganization of the actin
cytoskeleton with the formation of membrane edge ruffles that
have previously been shown to be an integral part of cellular
motility. We analyzed VEGF-stimulated formation of mem-
brane ruffles in the PAEKDR cell lines. Treatment of quiescent
cells with VEGF for 15 min resulted in the formation of mem-
brane ruffles in a small percentage ofmock-transfected cells (V)
(Fig. 3C), whereas amajority ofmutant cells showedmore strik-
ing edge ruffles (Fig. 3C). In contrast, WT TIMP-3 cells (Fig.
3C) did not formmembrane ruffles in response to VEGF. These
data provide convincing evidence that mutant TIMP-3 is an
inefficient inhibitor and likely an enhancer of VEGF-induced
EC responses.
S156C TIMP-3 Increases Differentiation but Not Survival
during VEGF-dependent Tube Formation—An in vitro angio-
genesis assay using a type 1 collagen substrate was employed to
study whether mutant TIMP-3 affected VEGF-stimulated tube
formation, which recapitulates the later stages of angiogenesis.
FIGURE 2. Endothelial cells expressing S156C TIMP-3 have increased levels of VEGFR-2with increased binding of VEGF. PAEKDR cells expressingWT (W)
or S156C TIMP-3 (M) or vector alone (V) were incubatedwith or without VEGF and analyzed for VEGF binding. A, 125I-VEGF165 binding is expressed as cpm/well.
B, concentration-dependent 125I-VEGF165 binding in PAEKDR cells. All results are the mean S.D. of a typical experiment. At least three independent experi-
ments gave comparable results. **, p 0.01 versus corresponding vector controls.C, VEGF165-mediated phosphorylation of VEGFR-2 in PAEKDR cells expressing
WT (W) or S156C TIMP-3 (M) or vector alone (V). Lysates from cells stimulated or not with 50 ng/ml VEGF for 10 min were separated by SDS-PAGF (10%) and
analyzed by immunoprecipitation (Ip) with an anti-KDR antibody followed by immunoblotting with an anti-phosphotyrosine antibody, 4G.10. D, KDR protein
was analyzed by immunoprecipitation and immunoblotting (Ib) of cell lysates using anti-KDR antibody (upper panel). Immunoblotting of cell lysates with
anti-actin antibody (lower panel) is shown. E, phosphorylation of ERK1 and ERK2 in response to VEGF was detected by immunoblotting with phosphospecific
ERK antibodies (top panel). Total protein levels of ERKwere determinedby immunoblottingwith anti ERK1/2 antibodies (bottompanels). F, quantitative (q) PCR
and RT-PCR for KDR were performed on control vector transfected, WT, and S156C mutant TIMP-3-expressing cells.
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In this assay cells were grown in
three-dimensional collagen gels in
the presence or absence of VEGF for
up to 8 days in culture. After 24 h,
VEGF stimulated the differentiation
of mock cells to form tube-like
structures that survived over the 8
days of culture (Fig. 3D). In contrast,
the ability of WT TIMP-3 cells to
form tube-like structures was
severely compromised (Fig. 3D).
However, mutant cells treated with
VEGF organized rapidly, forming
extensive tubular networks, but by
day 5 the tubular structures started
to regress and collapse. Both WT
TIMP-3 and mutant cells exhibited
morphologic features characteristic
of cell death relative to mock cells
under basal conditions (Fig. 3D).
These data suggest that mutant
TIMP-3 might potentiate RPE-
driven angiogenesis by increasing
VEGF signaling via elevated
VEGFR-2.
DecreasedMMP Inhibitory Activ-
ity and Increased VEGFR-2 Levels in
Timp-3S156C/S156C Mice—Spleen
and posterior pole eye tissue from
homozygous mice carrying the
SFD-associated S156C mutation
(28) were analyzed for MMP inhib-
itory activity and gelatinase activity
by reverse zymography and zymog-
raphy, respectively. Spleen tissue
from Timp-3S156C/S156C mutant
mice showed a complete absence of
TIMP-3 activity in both 24- and
28-kDa (glycosylated) forms (Fig.
4a, upper panel) with a correspond-
ing increase in MMP-9 activity (Fig.
4b, upper panel). Interestingly the
TIMP-3 activity in the retinae of
Timp-3S156C/S156Cmutant mice was
markedly decreased (Fig. 4a, lower
panel), however, with no corre-
sponding increase in MMP-9 (Fig.
5b, lower panel). It does appear that
the remnant 28-kDa MMP inhibi-
tory species seen in the eyes of the
mutant mice could likely be other
TIMPs (either 28-kDa TIMP-1 or
29-kDa TIMP-4) based on similar
bands observed in the retinae of
Timp-3 null mice (data not shown). These TIMPs likely com-
pensate for loss of TIMP-3 activity and might also explain the
absence of increased MMP activity in the retinae of Timp-
3S156C/S156Cmice. These results suggest that the effect of S156C
Timp-3 mutation on the MMP inhibitory function of the pro-
tein is tissue and cell type-specific.
VEGFR-2 and phosphorylated VEGFR-2 (pVEGFR-2) levels
were examined in the retina/choroid of mutant mice by immu-
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noprecipitation and Western blotting experiments. Increased
expression of VEGFR-2 (Fig. 4c,middle panel) as well as phos-
phorylated VEGFR-2 (Fig. 4c, upper panel) was observed in the
eyes of homozygous TIMP-3S156C/S156C relative to heterozy-
gous TIMP-3S156C/ or wild-type mice. Immunofluorescence
staining of mouse eyes with anti VEGFR-2 antibody revealed a
stronger labeling of choriocapillaris from Timp-3S156C/S156C
compared with wild-type littermates (Fig. 4d).
Increased VEGFR-2 in Human Eyes with Sorsby Fundus
Dystrophy—To determine whether our results showing that
mutant TIMP-3 causes an up-regulation of VEGFR-2 occurred
in the human disease, we performed immunohistochemical
analysis on a post-mortem eye of a 77-year-old woman with
SFD. As described previously (24), the SFD eye showed an
advanced stage of the disease with a marked loss of almost the
entire photoreceptor layer and gliosis of the remaining retina
(Fig. 5, a and b). The large deposits located between the RPE
and elastin sublayer of the Bruch membrane were TIMP-3-
positive (24) (Fig. 5e) and showed strong VEGFR-2 immunore-
activity (Fig. 5g). In the non-diseased normal eye TIMP-3 was
localized to the Bruch membrane and the choriocapillary bed
matrix as described previously (29) (Fig. 5d). Interestingly, we
observed that TIMP-3 immunoreactivity was apparently
reduced, whereas VEGFR-2 immunoreactivity was increased in
the deposits underlying areaswith RPE atrophy. Control tissues
incubated with nonimmune mouse IgG in lieu of the anti
TIMP-3 or VEGFR-2 antibody showed minimal background
immunoreactivity (Fig. 5h).
DISCUSSION
SFD is a rare autosomal dominant, fully penetrant disease
that commonly manifests as a hemorrhagic maculopathy sec-
ondary to choroidal neovascularization (12). The onset of
symptoms typically occurs in the third to fifth decades of life
with rapidly evolving loss of central vision or increasing nycta-
lopia (night blindness) over the course of several years (30, 31).
The clinical features of SFD very closely resemble those of age-
related macular degeneration, distinguished from each other
primarily on the basis of age of onset of symptoms and family
history. Given that mutations in TIMP-3 cause SFD, we rea-
soned it to be important to determine the role played by
TIMP-3 protein in pathophysiological responses of the retina.
In this study we demonstrate that the expression of mutant
S156C TIMP-3 in vascular endothelial cells augments VEGF-
induced angiogenesis that is mediated by elevated levels and
activation of functional surface VEGFR-2, which could poten-
tially play a crucial role in the development of choroidal neo-
vascularization in the disease. There has been an increasing
debate on whether the SFD mutant TIMP-3 results in a loss of
function, gain of function, or dominant-negative effect for the
protein (32, 33).
The identification of TIMP-3 as an endogenous inhibitor of
VEGFR-2-mediated angiogenesis (8) led us to postulate that
S156C TIMP-3, a mutation that results in an earlier onset phe-
notype as well as prominent choroidal neovascularization,
might be deficient in this angiogenesis inhibitory function. A
recent report determined that recombinant S156C TIMP-3
retains its anti-angiogenic activities with its ability to block the
binding of VEGF to VEFGR-2 and inhibit tube formation by
mouse aortic endothelial cells in the fibrin bead assay (33). In
FIGURE 3. S156C TIMP-3 is an inefficient inhibitor of VEGF-mediated EC proliferation,migration, and actin reorganization. Serum-starved PAEKDR cells
expressingWT (W) or S156C TIMP-3 (M) or vector alone (V) were incubatedwith orwithout VEGF and analyzed for proliferation,migration, actin reorganization,
and tube formation.A, proliferationof endothelial cells in response toVEGF (15ng/ml) for 40h (right panel). [3H]Thymidine incorporationwasmeasuredduring
the last 4 hof incubation. Optimal concentration of 15 ng/mlwas determined fromadose-response curve generatedusing PAEKDR vector-transfected cells (left
panel). p 0.01 (**) and p 0.05 (*) versus unstimulated controls. B, migration of endothelial cells toward VEGF (50 ng/ml) (right panel). Optimal concentration
of 50ng/mlwas determined fromadose-response curve generatedusing PAEKDR vector-transfected cells (left panel).Migrating cell number is expressed as the
means S.E. of quadruplicate samples.C, actin reorganization in PAEKDR cells stimulatedwith orwithout 50ng/ml VEGF for 15min at 37 °C. Thearrows indicate
membrane edge ruffling.Magnification1000.D, PAEKDR cells expressingWT (W) or S156C TIMP-3 (M) or vector alone (V) were cultured between two layers of
type 1 collagen gel in the presence or absence of 50 ng/ml VEGF as indicated. Pictures were taken at the indicated times after inoculation. Images are of
representative microscope fields (200).
FIGURE 4. Timp-3S156C/S156C mice have reduced TIMP-3 activity and
increased expression of VEGFR-2. Spleen (a and b upper panels) and retina/
choroids (a and b lower panels) of Timp-3/ (WT), Timp-3S156C/S156C (KI), or
Timp-3S156C/ (HET) were subjected to reverse zymography (a) and zymogra-
phy (b). Retina/choroid lysates were immunoprecipitated (Ip) with anti-
VEGFR-2 antibodies (c) followed by Western blot analysis with anti VEGFR-2
antibodies (middle panel) or anti-phosphotyrosine antibody (top panel).
Lysates were immunoblottedwith antibodies to actin (bottom panel) to stan-
dardize for protein loading. d, cryosections from WT and T3S156/S156 mouse
eyes were analyzed by immunofluorescence staining with anti-VEGFR2 anti-
body using Texas Red-conjugated goat anti-mouse secondary antibody. Red
staining indicated localization of VEGFR-2. INL, inner nuclear layer;ONL, outer
nuclear layer; CC, choriocapillaris.
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contrast, aortic endothelial cells frommice deficient in TIMP-3
showed a significantly increased tube formation and vessel out-
growth as well as VEGFR-2 downstream signaling (35). Inter-
estingly, in our study S156C TIMP-3 expression resulted in an
increase in the levels of themature formofVEGFR-2 protein on
the surface of endothelial cells. Elevated membrane-associated
VEGFR-2 was sufficient to increase VEGF binding and subse-
quent VEGR-2 autophosphorylation and mitogen-activated
protein kinase phosphorylation with downstream conse-
quences of enhancedVEGF-dependentmigration and tube for-
mation in vitro. It should be noted
that S156C TIMP-3 protein did not
augment VEGF-dependent prolif-
eration or the survival phase of in
vitro angiogenesis. Because both
recombinant TIMP-3 proteins (WT
and S156C TIMP-3) can block the
binding of VEGF to VEGR-2 (33),
the loss of angio-inhibitory activity
seen with mutant TIMP-3 in our
study is most likely because of the
up-regulation of the VEGFR-2, sug-
gesting a gain of function. One pos-
sibility for the surprising findings in
the present study is the use of ocular
tissue from S156C Timp-3 mutant
mice as compared with liver and
chondrocytes in the previous study
(33). Our results suggest that in
endothelial cells, S156C TIMP-3
shows reduced binding to the
ECM and increased glycosylation.
Whether this property of the
mutant protein has a specific effect
in the retina as a consequence of its
interaction with unique matrix pro-
teins in Bruch’s membrane is cur-
rently being investigated.
The exact molecular mechanism
by which S156C TIMP-3 increases
membrane-associated VEGFR-2 is
unknown. In PAE-KDR cells the
VEGFR-2 protein is expressed
under the control of the human
cytomegalovirus promoter. The
expression of mutant TIMP-3
results in an increase in membrane-
bound VEGFR-2 protein in endo-
thelial cells, whereas the relative
amount of specific mRNA level
remains stable, suggesting a post-
transcriptional up-regulation of the
receptor independent of the
VEGFR-2 promoter, similar to that
observed previously in PAE/KDR
cells cultured under hypoxic condi-
tions (27).
Pulse-chase experiments show
that VEGFR-2 is initially synthesized as an immature 150-kDa
protein and is rapidly glycosylated to a 200-kDa intermediate
form and further glycosylated at a slower rate to a mature 230-
kDa protein that is expressed on the cell surface (36). Our stud-
ies confirmed the presence of three VEGFR-2 isoforms in the
plasma membrane of PAEKDR cells. In addition to the mature
protein, mutant TIMP-3 markedly increased the levels of the
immature form compared with cells expressing WT TIMP-3.
These data indicate that mutant TIMP-3 has distinctive effects
on the early steps of maturation of the receptor. It has been
FIGURE5. IncreasedaccumulationofVEGFR-2 inhumanSFD.Paraffin embedded sectionsof apost-mortem
human eye with SFD (b, e, g, and h) and an age-matched control non-diseased eye (a, c, d, f) were subjected to
hematoxylin and eosin staining (a and b) immunohistochemistry with antibodies to VWF (c), TIMP-3 (d and e),
VEGFR-2 (f and g) and control nonspecific IgG (h). *, sub-RPE deposits. RPE, retina pigment epithelium; ONL,
outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer.
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recently reported that novel highly efficient intrabodies can
bind newly synthesizedVEGFR-2 in the endoplasmic reticulum
and block receptor transport to the cell surface (37, 38). It is an
interesting possibility thatWT andmutant TIMP-3may differ-
entially affect immature receptor translocation via distinct
interactions with newly synthesized VEGFR-2 in the endoplas-
mic reticulum. In addition, it has been also suggested that 3
integrin negatively regulates VEGFR-2 expression (39) and that
caveolin plays a role in VEGFR-2 internalization (40). The role
of TIMP-3 in these mechanisms is unknown.
The ADAMs family of membrane-spanning proteins com-
bines features of both adhesionmolecules and proteinases (41).
ADAM17 (also known as tumor necrosis factor--converting
enzyme), the sole mammalian cell surface-associated metallo-
proteinase sheddase so far identified, can affect the shedding of
transmembrane-anchored proteins such as tumor necrosis fac-
tor- (42), L-selectin (43), and interleukin-6 receptor (44) that
are sensitive to TIMP-3. Recent studies have reported that
recombinant S156C TIMP-3 protein can inhibit ADAM17 and
aggrecan-cleaving MMPs (33). A TIMP-3-sensitive metallo-
proteinase also mediates the shedding of transmembrane pro-
tein syndecan-1 (45). Because VEGFR-2 can be proteolytically
cleaved fromendothelial cells (46) and SFDmutantTIMP-3 has
attenuatedMMP inhibitory activities, it is possible that mutant
TIMP-3 could regulate the shedding of VEGFR-2 from endo-
thelial cells. Taken together, these data indicate that the up-reg-
ulation of surface VEGFR-2 by mutant TIMP-3 is a dynamic
process; the exact molecular mechanism(s) by which this
occurs remains to be determined.
Ten independent mutations causing SFD have been identi-
fied to date. Seven of the 10mutations introduce a new cysteine
residue at the C terminus (S156C, G166C, G167C, Y168C,
S170C, Y172C, and S181C). The E139Xmutation, which intro-
duces a stop codon at residue 139, results in an odd number of
cysteine residues at the C terminus. The last two mutations, a
mutation of the intron 4/exon 5 splice acceptor site as well as
H158Rmutation, do not create a new cysteine residue. Previous
studies have reported that some TIMP-3mutations gave rise to
several additional higher molecular mass protein complexes
(possibly TIMP-3 dimers) that retained their ability to inhibit
MMPs and localized to the ECMwhen expressed in COS7 cells
(17). Higher molecular weight complexes were also detected in
mutantmurine TIMP-3S156C/S156C fibroblast cells but lost their
inhibitory activity (47). In contrast to these findings, we have
detected a heavily glycosylated variant of mutant TIMP-3 pro-
tein with reduced MMP inhibitory activity and attenuated
binding to the ECM in endothelial cells. The discrepancy
between previous reports and ours is most likely because of
differences in cell type examined. Reduced binding of mutant
TIMP-3 to the ECM could be a result of an excessive glycosy-
lation, which can potentially decrease its apparent affinity for
the ECM, presumably bymasking basic residues (16). Excessive
glycosylation might also lead to a reduction of MMP inhibitory
activity of mutant TIMP-3, presumably by a conformation
change or reduced ECM binding (48). Indeed, our data have
shown that the unglycosylated form of mutant TIMP-3 in the
ECM, but not the glycosylated form in the conditioned
medium, retained someMMP inhibitory activity.We have pre-
viously demonstrated that expression of S156C TIMP-3 in
human RPE cell line results in reduced inhibition ofMMPs and
increased activation of MMP2 and MMP9 (10). More recently,
the inability of the S156C mutation to inhibit MT1-MMP acti-
vation of pro-MMP2 has been confirmed independently in
addition to the finding of accumulation of a turnover-resistant
fraction of mutant TIMP-3 protein in RPE cells (26). Examina-
tion of the choriocapillaris and sub-RPE deposits in mice
expressing mutant TIMP-3 and in an SFD human eye confirms
the presence of increased VEGFR-2 protein.
In summary, we have shown that SFD S156C mutation spe-
cifically and dynamically up-regulates surface VEGFR-2 level
and activity resulting in enhanced VEGF-dependent angiogen-
esis. This points to a novel mechanism for the regulation of
angiogenesis by S156C TIMP-3 in SFD. Systemic bevacizumab
has been recently shown to be a promising treatment option for
choroidal neovascularization in a patient with SFD (34). Our
data also show that S156C TIMP-3 is highly glycosylated, solu-
ble, and inefficient in MMP inhibitory activity, suggesting that
in addition to anti VEGF therapies, MMP inhibitors might pro-
vide therapeutic benefit.
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